inspection – Page 269

Deviation recurrence across batches during scale-up – regulatory impact assessment case study

Investigating Deviation Recurrence During Scale-Up: A Regulatory Perspective In pharmaceutical manufacturing, scale-up processes often expose underlying inefficiencies or failures. One crucial challenge that many manufacturers encounter is the recurrence of…

Batch executed with expired SOP during inspection preparation – regulatory impact assessment case study

Regulatory Impact of Executing a Batch with Expired SOP: A Comprehensive Case Study In the dynamic field of pharmaceutical manufacturing, adherence to Standard Operating Procedures (SOPs) is paramount. However, the…

Batch executed with expired SOP during changeover – regulatory impact assessment case study

Regulatory Implications of Executing a Batch with an Expired SOP During Changeover: A Case Study In the pharmaceutical manufacturing sector, adherence to standard operating procedures (SOPs) is critical to ensuring…

Batch executed with expired SOP during scale-up – regulatory impact assessment case study

Case Study: Executing a Batch with Expired SOP During Scale-Up and Its Impact on Compliance In the high-stakes environment of pharmaceutical manufacturing, adherence to Standard Operating Procedures (SOPs) is non-negotiable.…

Deviation recurrence across batches during changeover – CAPA ineffectiveness identified

Analyzing Deviation Recurrence in Batches During Changeover: Lessons from CAPA Failures In an increasingly regulated pharmaceutical environment, the occurrence of deviations during batch changeovers can significantly disrupt manufacturing operations. Such…

Deviation recurrence across batches during commercial campaign – root cause analysis failure explained

Case Study: Investigating Deviation Recurrence in a Commercial Campaign In pharmaceutical manufacturing, ensuring compliance with Good Manufacturing Practice (GMP) is crucial for maintaining product quality and safety. However, deviations can…

Unapproved process parameter change during tech transfer – FDA inspection observation breakdown

Breakdown of FDA Inspection Observations Related to Unapproved Process Parameter Changes During Tech Transfer In the pharmaceutical manufacturing environment, process integrity is essential to ensure compliance with Good Manufacturing Practices…

Process change implemented without QA approval during scale-up – CAPA ineffectiveness identified

Case Study: Addressing Unapproved Process Changes During Scale-Up and Evaluating CAPA Effectiveness In the pharmaceutical manufacturing industry, maintaining compliance with regulatory standards is critical. A significant risk arises when process…

Process change implemented without QA approval during inspection preparation – regulatory impact assessment case study

Assessing the Regulatory Implications of Unapproved Process Changes During Inspection Preparation In a highly regulated industry like pharmaceuticals, deviations from established processes can lead to significant compliance issues, especially during…

Deviation recurrence across batches during tech transfer – root cause analysis failure explained

Analyzing Deviation Recurrence Across Batches During Technology Transfer: A Comprehensive Case Study In the robust environment of pharmaceutical manufacturing, maintaining compliance and ensuring product integrity is paramount. A notable challenge…

Critical IPC skipped during scale-up – FDA inspection observation breakdown

Investigation of Critical IPC Missing During Scale-Up and FDA Inspection Outcomes The successful scale-up of pharmaceutical products can be riddled with challenges, particularly in manufacturing controls where critical In-Process Controls…

Unapproved process parameter change during commercial campaign – CAPA ineffectiveness identified

Addressing Unapproved Process Parameter Changes During a Commercial Campaign In the realm of pharmaceutical manufacturing, adherence to established process parameters is paramount to ensure product quality and compliance with regulatory…